To avec succès conduct U.S. essais cliniques for RCI001, we have completed a business accord with Ora, a clinical research organization specializing in eye diseases, and are entering full-scale clinical operations.
With the production of essai clinique raw materials now complete, we are making preparations in close collaboration with Ora to avec succès complete the U.S. essai clinique de Phase 2 in 2022.
Ora, Inc., a U.S.-based CRO and SMO specializing in ophtalmique diseases, will conduct the essai clinique using its proprietary CAE™ (Controlled Adverse Environment) model — a more efficient and rapid approach sur la base de extensive experience conducting sécheresse oculaire essais cliniques.
To avec succès complete the U.S. essai clinique, we have recruited Chef de l'équipe clinique Yuseung Ha, who has years of clinical research experience at IQVIA, and restructured the clinical team as an independent department to build a more agile clinical response environment.